MOMENTA APPLIES TO LAUNCH TRIAL OF ANTICOAGULANT

Momenta Pharmaceuticals announced that it has submitted an electronic investigational new drug application to the FDA to begin a Phase I study of M118, the company's lead development candidate. M118 is an anticoagulant designed specifically to treat acute coronary syndromes (ACS).

The company developed M118 using its proprietary technology for the detailed analysis and design of complex sugar therapeutics. By isolating, characterizing and engineering the key sugar structures within heparin that contribute to anticoagulation, the company designed a proprietary compound that it believes could provide baseline anticoagulant therapy to treat ACS patients who require a coronary intervention. M118 is designed to be a reversible and monitorable anticoagulant that has a pharmacokinetic profile similar to a low-molecular-weight heparin that can be used in a variety of ACS treatment paths.